Form 4: Processa Pharmaceuticals CFO Granted Over 1.7 Million Restricted Stock Units

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted was granted 1,775,044 Restricted Stock Units, with vesting scheduled through January 2028.

Summary

• Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA), was granted 1,775,044 Restricted Stock Units (RSUs) on July 24, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest in a staggered manner: one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.
• Of the granted RSUs, 1,753,212 shares are subject to stockholder approval of the revised 2019 Omnibus Incentive Plan.
• Following this transaction, Russell Skibsted beneficially owns 1,803,044 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a standard executive compensation practice that aligns management incentives with shareholder interests, though a portion is subject to stockholder approval.

Positives

• The grant of Restricted Stock Units aligns the Chief Financial Officer's incentives with long-term shareholder value creation.
• The vesting schedule encourages long-term retention of key management personnel.

Negatives

• A significant portion of the RSU grant (1,753,212 shares) is contingent upon stockholder approval of the revised 2019 Omnibus Incentive Plan, introducing a condition to the full realization of the grant.

Risks

• The full realization of 1,753,212 Restricted Stock Units is contingent on stockholder approval of the revised 2019 Omnibus Incentive Plan, posing a risk that the full grant may not be realized if approval is not obtained.

Future Outlook

The future outlook indicates a structured vesting schedule for the granted Restricted Stock Units, with shares converting to common stock incrementally from January 2026 through January 2028, contingent on continued employment and stockholder approval for a portion of the grant.

Industry Context

This RSU grant is a standard form of executive compensation in the biotechnology and pharmaceutical industries, designed to align management interests with long-term company performance and shareholder returns. Such grants are common for retaining key talent and incentivizing strategic growth.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a Chief Financial Officer is a common practice in the pharmaceutical industry, comparable to compensation structures seen at companies like BioNTech SE or Moderna, Inc., which frequently use equity awards to incentivize executives.
• The multi-year vesting schedule (2026-2028) is typical for long-term incentive plans, similar to those adopted by peers such as Gilead Sciences, Inc. or Amgen Inc., ensuring executive retention and commitment over several fiscal periods.
• The contingency of a portion of the grant on stockholder approval of an incentive plan revision is also a standard corporate governance practice, ensuring alignment with shareholder interests, as seen in similar plan updates across the S&P 500.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting of RSUs, but also increased alignment of executive interests with long-term company performance.
• Employees: The grant to a key executive may signal stability and commitment from leadership, potentially boosting morale.

Next Steps

• Stockholders will need to vote on the approval of the revised 2019 Omnibus Incentive Plan, which affects 1,753,212 of the granted RSUs.
• The first tranche of RSUs will vest on January 1, 2026.
• Subsequent monthly vesting will occur until the RSUs are fully vested on January 1, 2028.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Restricted Stock Units, RSU, Executive Compensation, SEC Form 4, Insider Transaction, Chief Financial Officer, Stock Grant, Omnibus Incentive Plan